RI
BOLD

RTW Investments’s Audentes Therapeutics, Inc BOLD Stock Holding History

RTW Investments’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-20,000
Closed -$365K – 35
2016
Q4 		$365K Hold
20,000
– – 0.14% 29
2016
Q3 		$356K Buy
+20,000
New +$304K 0.11% 32

Other funds holding BOLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

RTW Investments's BOLD Position: Q1 2017 in Review

RTW Investments sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2017, closing a stake of 20,000 shares — an estimated $365K sold.

RTW Investments first reported a position in BOLD in Q3 2016 and held it in 2 quarters. The position peaked at $365K in Q4 2016. 58 funds tracked by Wall St. Rank hold BOLD as of Q1 2017.

  • RTW Investments reported no remaining Audentes Therapeutics, Inc position as of Q1 2017 after selling out during the quarter.
  • RTW Investments sold 20,000 Audentes Therapeutics, Inc shares in Q1 2017, an estimated $365K.
  • RTW Investments first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 2 quarters.
  • RTW Investments's Audentes Therapeutics, Inc position peaked at $365K in Q4 2016.
  • 58 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2017.

Based on RTW Investments's 13F filing for Q1 2017, filed 15 May 2017.